This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Reduction of Bacteria in MRSA Positive Ulcers

This study has been terminated.
(limited recruitment)
Information provided by:
Nitric BioTherapeutics, Inc Identifier:
First received: October 10, 2008
Last updated: January 18, 2012
Last verified: January 2012
The purpose of this study is to determine if gaseous nitric oxide is effective in the treatement of bacteria in MRSA positive ulcers

Condition Intervention Phase
Leg Ulcer Pressure Ulcer Drug: Nitric Oxide Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Clinical Trial on the Reduction of Bacteria (Including MRSA) in MRSA Positive Ulcers and Lesions

Resource links provided by NLM:

Further study details as provided by Nitric BioTherapeutics, Inc:

Primary Outcome Measures:
  • Reduction in bacteria [ Time Frame: Post Treatment Day 3 ]

Secondary Outcome Measures:
  • Incidence of adverse events [ Time Frame: 3 days ]

Estimated Enrollment: 20
Study Start Date: January 2009
Study Completion Date: June 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nitric Oxide
gaseous nitric oxide delivered topically for 30 minutes
Drug: Nitric Oxide
1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have given written informed consent
  • Must be 19 years of age or over
  • Must have an ulcer or lesion in which the presence of MRSA has been positively identified but which is not clinically infected.
  • Must have an Ulcer / Lesion size not to extend beyond the inner borders of the wound cover

Exclusion Criteria:

  • Is a female who is pregnant, nursing, or of child bearing potential who is not using an adequate form of contraception (or abstinence)
  • Is < 19 years of age
  • Has a clinically infected ulcer
  • Has an Ulcer / Lesion that is currently treated or has been treated with a topical antimicrobial agent during 3 days prior to enrolment.
  • Has been using systemic antibiotics during 7 days prior to enrolment into this study.
  • Has an Ulcer / Lesion which is identified as malignant in origin (e.g., Marjolin's ulcer)
  • Has an Ulcer / Lesion size beyond the inner borders of the wound cover
  • Is septic or has other signs of an invasive infection
  • Has used any other investigational product within 30 days preceding study participation.
  • Suffers from a condition, which, in the opinion of the Investigator,would compromise his or her safety.
  • Suffers from a condition which, in the opinion of the Investigator, would compromise the quality of the data.
  • Has a known allergy to any of the products that are part of this protocol
  • Suffers from a condition which, in the opinion of the Investigator, would seriously interfere negatively with the normal parameters of immune response to an infection.
  • Is using any of the prohibited concomitant medications or treatments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00771368

Canada, British Columbia
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 1M9
Sponsors and Collaborators
Nitric BioTherapeutics, Inc
  More Information

Responsible Party: President & CEO, Nitric BioTherapeutics, Inc. Identifier: NCT00771368     History of Changes
Other Study ID Numbers: CTP 7
Study First Received: October 10, 2008
Last Updated: January 18, 2012

Additional relevant MeSH terms:
Leg Ulcer
Pressure Ulcer
Pathologic Processes
Skin Ulcer
Skin Diseases
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Protective Agents processed this record on September 19, 2017